Chiasma Set to Join Russell 3000® Index
June 27, 2019 16:10 ET
|
Chiasma, Inc.
WALTHAM, Mass., June 27, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Provides Update on Ongoing Mycapssa® Phase 3 Clinical Trials
June 27, 2019 16:05 ET
|
Chiasma, Inc.
On track with U.S. Phase 3 CHIASMA OPTIMAL trial; data now expected by mid-Q3 2019 Target enrollment completed in ongoing Phase 3 MPOWERED™ trial; data expected in 2H 2020 WALTHAM, Mass., June 27,...
Chiasma Strengthens Leadership Team Ahead of Anticipated Commercial Availability of Mycapssa®
June 05, 2019 16:05 ET
|
Chiasma, Inc.
Appoints pharma commercial veteran Raj Kannan as Chief Executive Officer Current CEO Mark Fitzpatrick to retain the role of President WALTHAM, Mass., June 05, 2019 (GLOBE NEWSWIRE) -- Chiasma,...
Chiasma and Lonza Announce Progression of Oral Octreotide Capsules Development and Definitive Commercial Supply Agreement
May 14, 2019 16:05 ET
|
Chiasma, Inc.
Chiasma recently completed enrollment of its CHIASMA OPTIMAL Phase 3 clinical trial of octreotide capsules, the first potential oral somatostatin analog for the maintenance treatment of...
Chiasma Reports First Quarter 2019 Results
May 09, 2019 16:05 ET
|
Chiasma, Inc.
WALTHAM, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma to Report First Quarter Financial Results on May 9, 2019
April 30, 2019 16:05 ET
|
Chiasma, Inc.
WALTHAM, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Announces Closing of $34.5 Million Offering of Common Stock and Full Exercise of Underwriters’ Option
April 03, 2019 09:25 ET
|
Chiasma, Inc.
WALTHAM, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Announces Pricing of Underwritten Public Offering of $30.0 Million of Common Stock
March 29, 2019 09:25 ET
|
Chiasma, Inc.
WALTHAM, Mass., March 29, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Announces Proposed Offering of Common Stock
March 28, 2019 16:01 ET
|
Chiasma, Inc.
WALTHAM, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Announces Three Poster Presentations at ENDO 2019
March 21, 2019 16:05 ET
|
Chiasma, Inc.
WALTHAM, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...